Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effects of Creatine Formulations on Exercise and Cognitive Performance

10 de novembro de 2026 atualizado por: Terence Moriarty, University of Northern Iowa

Effects of Creatine Monohydrate Versus a Multi-Ingredient Creatine Formulation on Exercise Performance, Cognitive Function, Hydration, and Gastrointestinal Tolerability

This study will examine whether a multi-ingredient creatine supplement produces different effects on exercise performance, cognitive function, hydration, and gastrointestinal symptoms compared with creatine monohydrate alone.

Approximately 16 healthy, physically active adults aged 18-40 years will participate. Each participant will take creatine monohydrate (5 grams per day) for 18 days and a multi-ingredient supplement containing creatine monohydrate (5 grams), sodium, potassium, magnesium, and taurine for another 18 days. The order of supplementation will be randomly assigned, with a 30-day break between conditions.

Participants will complete laboratory testing before and after each supplementation period. Testing will include bench press exercise to assess muscular endurance, repeated high-intensity cycling tests to assess exercise performance, and a computerized cognitive task to measure attention and reaction time. Researchers will also assess hydration, selected blood markers, perceived exertion, and gastrointestinal symptoms.

The findings may help determine whether adding electrolytes and taurine to creatine provides additional benefits or produces different physiological responses compared with creatine monohydrate alone.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

16

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Iowa
      • Cedar Falls, Iowa, Estados Unidos, 50614
        • Recrutamento
        • Wellness and Recreation Center
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 40 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Adults aged 18-40 years.
  • Apparently healthy individuals who are physically active and capable of performing vigorous exercise.
  • Willing and able to complete repeated maximal-intensity cycling tests, bench press exercise, and cognitive assessments.
  • Willing to consume both assigned dietary supplement formulations for 18 days each, separated by a 30-day washout period.
  • Willing to refrain from taking additional creatine or electrolyte supplements during the study, including the washout period.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • History of cardiovascular, metabolic, renal, neurological, or musculoskeletal conditions that may contraindicate vigorous exercise or interfere with study outcomes.
  • Current injury or physical limitation that would prevent safe completion of the exercise testing procedures.
  • Current pregnancy or plans to become pregnant during the study.
  • Recent creatine supplementation prior to enrollment.
  • Current use of medications or dietary supplements that may interfere with creatine metabolism, hydration status, exercise performance, cognitive function, or participant safety.
  • Known allergy, intolerance, or contraindication to any ingredient in the study supplements.
  • Unwillingness or inability to comply with supplementation, washout, or laboratory testing requirements.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Creatine Monohydrate Followed by Multi-Ingredient Creatine

Participants will receive creatine monohydrate (5 g/day) with sugar-free flavoring for 18 consecutive days, followed by a 30-day washout period. Participants will then receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period.

Participants will consume 5 g/day of creatine monohydrate mixed with sugar-free flavoring for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

Participants will consume a multi-ingredient dietary supplement containing creatine monohydrate (5 g), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) daily for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

Experimental: Multi-Ingredient Creatine Followed by Creatine Monohydrate

Participants will receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for 18 consecutive days, followed by a 30-day washout period. Participants will then receive creatine monohydrate (5 g/day) with sugar-free flavoring for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period.

Participants will consume 5 g/day of creatine monohydrate mixed with sugar-free flavoring for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

Participants will consume a multi-ingredient dietary supplement containing creatine monohydrate (5 g), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) daily for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Total Bench Press Repetitions
Prazo: Baseline and Day 18 of each supplementation period.

Total number of repetitions completed across three sets of bench press exercise at 70% of baseline one-repetition maximum (1RM), performed to volitional fatigue with one minute of rest between sets.

Baseline and Day 18 of each supplementation period.
Peak Power During Repeated Wingate Tests
Prazo: Baseline and Day 18 of each supplementation period.

Peak power output (watts) measured during three consecutive 30-second Wingate cycling tests, performed with standardized recovery periods.

Baseline and Day 18 of each supplementation period.
Mean Power During Repeated Wingate Tests
Prazo: Baseline and Day 18 of each supplementation period.

Mean power output (watts) measured during each of three 30-second maximal-effort Wingate cycling tests.

Baseline and Day 18 of each supplementation period.
Total Work During Repeated Wingate Tests
Prazo: Baseline and Day 18 of each supplementation period.

Total mechanical work (kilojoules) completed across three 30-second Wingate cycling tests.

Baseline and Day 18 of each supplementation period.
Stroop Interference Reaction Time
Prazo: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).

Cognitive performance assessed using a computerized Stroop task completed before exercise and during recovery between repeated Wingate tests. Reaction time (milliseconds) will be used to evaluate changes in cognitive performance as exercise-induced fatigue accumulates.

Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).
Stroop Task Accuracy
Prazo: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).

Percentage of correct responses during a computerized Stroop task administered before exercise and during recovery between repeated Wingate cycling tests.

Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Wingate Fatigue Index
Prazo: Baseline and Day 18 of each supplementation period.

Percentage decline in power output during repeated Wingate tests.

Baseline and Day 18 of each supplementation period.
Rating of Perceived Exertion
Prazo: Baseline and Day 18 of each supplementation period.

Perceived exertion assessed using the Borg 6-20 scale following each Wingate.

Baseline and Day 18 of each supplementation period.
Blood Lactate Concentration
Prazo: Baseline and Day 18 of each supplementation period.

Blood lactate concentration (mmol/L) measured following each Wingate.

Baseline and Day 18 of each supplementation period.
Urine Specific Gravity
Prazo: Baseline and Day 18 of each supplementation period.

Urine specific gravity assessed before and after exercise to evaluate hydration status.

Baseline and Day 18 of each supplementation period.
Blood Sodium Concentration
Prazo: Baseline and Day 18 of each supplementation period.

Sodium concentration measured using an i-STAT analyzer.

Baseline and Day 18 of each supplementation period.
Blood Potassium Concentration
Prazo: Baseline and Day 18 of each supplementation period.

Potassium concentration measured using an i-STAT analyzer.

Baseline and Day 18 of each supplementation period.
Gastrointestinal Symptom Severity
Prazo: Baseline and Day 18 of each supplementation period.

Daily 0-10 ratings of bloating, abdominal discomfort, nausea, diarrhea, constipation, reflux, and overall gastrointestinal discomfort.

Baseline and Day 18 of each supplementation period.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

13 de novembro de 2026

Conclusão Primária (Estimado)

31 de maio de 2027

Conclusão do estudo (Estimado)

31 de maio de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

5 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de novembro de 2026

Primeira postagem (Real)

16 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • IRB-FY27-58

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .